Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Camberwell, VIC, AU. The stock last traded at $1.24, up 5.98% on the session, giving a market capitalisation of $2.8M. On trailing twelve-month figures it carries a trailing P/E of -0.04, a net margin of 0.0%. Its beta of 3.27 implies it has historically moved more than the broad market.
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Propanc Biopharma, Inc. is most often compared with the following Healthcare names: